FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

hours per response:

OMB Number:	3235-0287
atimated average burden	

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			2. Issuer Name and Ticker or Trading Symbol KORU Medical Systems, Inc. [KRMD]		ionship of Reporting F all applicable) Director Officer (give title	to Issuer 10% Owner Other (specify	
(Last) 1717 ARCH STRE 37TH FLOOR	(First) EET	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 09/30/2023		below)		below)
(Street) PHILADELPHIA (City)	PA (State)	19103 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	dual or Joint/Group Fi Form filed by One F Form filed by More	Reporting	Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (li 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(11150: 4)
Common Stock	09/30/2023		A		5,484	A	\$0 ⁽¹⁾	7,463,918	ī	By Horton Capital Partners Fund, LP ⁽²⁾
Common Stock								2,344,658	I	By Horton Freedom, L.P. ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)	ction	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Security Securities	Ownership Form: Bei Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

				Code	v
1. Name and Addre		ng Person [*]			
(Last)	(Firs	t)	(Middle)		
1717 ARCH ST	REET				
37TH FLOOR					
(Street) PHILADELPH	IA PA		19103		
(City)	(Stat	e)	(Zip)		
1. Name and Address Horton Capit		-			
(Last)	(Firs	t)	(Middle)		
1717 ARCH ST	REET				
37TH FLOOR					
(Street)					
PHILADELPH	IA PA		19103		

(City)	(State)	(Zip)				
1. Name and Address of Reporting Person* <u>Horton Capital Partners, LLC</u>						
- Itorton Capitari	<u>artifolis, EEC</u>					
(Last)	(First)	(Middle)				
1717 ARCH STREE	Γ					
37TH FLOOR						
(Street)						
PHILADELPHIA	PA	19103				
(City)	(State)	(Zip)				
1. Name and Address of Parton Capital Parton Capita	Reporting Person* artners Fund, L.P.					
(Last)	(First)	(Middle)				
1717 ARCH STREE	Γ					
37TH FLOOR						
(Street)						
PHILADELPHIA	PA	19103				
(City)	(State)	(Zip)				
1. Name and Address of F	Reporting Person*					
Horton Freedom,	<u>L.P.</u>					
(Last)	(First)	(Middle)				
1717 ARCH STREE	Γ					
37TH FLOOR						
(Street)						
PHILADELPHIA	PA	19103				
(City)	(State)	(Zip)				

Explanation of Responses:

- 1. See Exhibit 99.1 to this Form 4 for explanation of note (1).
- 2. See Exhibit 99.1 to this Form 4 for explanation of note (2).

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

10/03/2023 /s/ Joseph M. Manko, Jr. /s/ Joseph M. Manko, Jr., Managing Member of Horton 10/03/2023 Capital Management, LLC /s/ Joseph M. Manko, Jr., 10/03/2023 Managing Member of Horton Capital Partners, LLC /s/ Joseph M. Manko, Jr., Managing Member of Horton Capital Partners, LLC, the General 10/03/2023 Partner of Horton Capital Partners Fund, LP /s/ Joseph M. Manko, Jr., Managing Member of Horton 10/03/2023 Capital Partners, LLC, the General Partner of Horton Freedom, L.P. ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXHIBIT 99.1 TO FORM 4

Explanation of Responses:

- (1) On September 30, 2023, Horton Capital Partners Fund, LP, a Delaware limited partnership ("HCPF"), was granted 5,484 shares of Repro Med Systems, Inc. (the "Issuer") common stock ("Common Stock") in consideration for Mr. Manko's service as a Director of the Issuer for the quarter ended September 30, 2023.
- (2) This Form 4 is filed jointly by Horton Capital Management, LLC, a Delaware limited liability company ("HCM"), Horton Capital Partners LLC, a Delaware limited liability company ("HCP"), HCPF, and Joseph M. Manko, Jr. Pursuant to investment advisory agreements, HCM maintains investment and voting power with respect to shares of Common Stock of the Issuer held by HCPF and Horton Freedom, L.P., a Delaware limited partnership ("Horton Freedom"). However, despite the delegation of investment and voting power to HCM, HCP may be deemed to be the beneficial owner of such Common Stock because, in the event HCM's investment advisory agreement with respect to such Common Stock is terminated, HCP has the right to assume HCM's discretionary investment and voting authority with respect to such Common Stock. HCP is the general partner of HCPF and Horton Freedom. Mr. Manko is the managing member of both HCM and HCP.

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.